3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Anti-allergens, oral
b. Antibiotics, inhaled
c. Anticoagulants
d. Antidepressants, other
e. Antidepressants, selective serotonin reuptake inhibitors (SSRIs)
f. Antidepressants, tricyclic
g. Antihyperuricemics
h. Antivirals, oral
i. Anxiolytics
j. Benign prostatic hyperplasia treatments
k. Beta-blockers
l. Bile salts
m. Bronchodilators, beta-agonist
n. Chronic obstructive pulmonary disease agents
o. Cough and cold
p. Erythropoiesis stimulating proteins
q. Glucocorticoids, inhaled
r. Hemophilia treatment
s. Hereditary angioedema (HAE) treatments
t. Hypoglycemics, incretin mimetics/enhancers
u. Immune globulins, intravenous
v. Immunomodulators, asthma
w. Lincosamides/oxazolidinones/streptogramins
x. Lipotropics, other
y. Lipotropics, statins
z. Multiple sclerosis agents
aa. aa.Pancreatic enzymes
ab. bb.Pediatric vitamin preparations
ac. cc.Prenatal vitamins
ad. dd.Pulmonary arterial hypertension agents, oral and inhaled
ae. ee.Sedative hypnotics
af. ff.Sickle cell anemia treatments
ag. gg.Thrombopoiesis stimulating proteins
ah. hh.Urea cycle disorder, oral
4. Public comment on new drugs to be reviewed for the Medicaid PDL:
a. Dificid suspension (oral)/Antibiotics, gastrointestinal
b. Nyvepria (subcutaneous)/Colony stimulating factors
c. Ibupak kit (oral)/nonsteroidal anti-inflammatory drugs (NSAIDs)
d. Venngel one kit (topical)/NSAIDs
e. Pataday extra strength over the counter (ophthalmic)/ophthalmics for allergic conjunctivitis
f. Eysuvis (ophthalmic)/ophthalmics, anti-inflammatory/immunomodulator
g. Impeklo lotion (topical)/steroids, topical very high
2. Retrospective drug utilization review (DUR): Conduent, LLC
a. Report on recent retrospective DUR interventions:
b. Report on recent retrospective DUR intervention outcomes:
c. Retrospective DUR proposals: (vote required)
3. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required)
a. Anxiolytic and sedative/hypnotics
b. HAE agents
c. Hyperlipidemia agents
d. Multiple sclerosis agents - new criteria (safety checks)
a. Aerosolized agents - metered-dose inhalers (MDIs): anticholinergic drugs
b. Aerosolized agents - MDIs: anti-inflammatory drugs
c. Aerosolized agents - MDIs: beta2 agonists (long-acting)
d. Aerosolized agents - MDIs: beta2 agonists (short-acting)
e. Antidepressant drugs – other
f. Antidepressant drugs – SSRIs
Apr 23, 2021 Drug Utilization Review Board (DURB) Agenda
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
a. Anti-allergens, oral
b. Antibiotics, inhaled
c. Anticoagulants
d. Antidepressants, other
e. Antidepressants, selective serotonin reuptake inhibitors (SSRIs)
f. Antidepressants, tricyclic
g. Antihyperuricemics
h. Antivirals, oral
i. Anxiolytics
j. Benign prostatic hyperplasia treatments
k. Beta-blockers
l. Bile salts
m. Bronchodilators, beta-agonist
n. Chronic obstructive pulmonary disease agents
o. Cough and cold
p. Erythropoiesis stimulating proteins
q. Glucocorticoids, inhaled
r. Hemophilia treatment
s. Hereditary angioedema (HAE) treatments
t. Hypoglycemics, incretin mimetics/enhancers
u. Immune globulins, intravenous
v. Immunomodulators, asthma
w. Lincosamides/oxazolidinones/streptogramins
x. Lipotropics, other
y. Lipotropics, statins
z. Multiple sclerosis agents
aa. aa.Pancreatic enzymes
ab. bb.Pediatric vitamin preparations
ac. cc.Prenatal vitamins
ad. dd.Pulmonary arterial hypertension agents, oral and inhaled
ae. ee.Sedative hypnotics
af. ff.Sickle cell anemia treatments
ag. gg.Thrombopoiesis stimulating proteins
ah. hh.Urea cycle disorder, oral
4. Public comment on new drugs to be reviewed for the Medicaid PDL:
a. Dificid suspension (oral)/Antibiotics, gastrointestinal
b. Nyvepria (subcutaneous)/Colony stimulating factors
c. Ibupak kit (oral)/nonsteroidal anti-inflammatory drugs (NSAIDs)
d. Venngel one kit (topical)/NSAIDs
e. Pataday extra strength over the counter (ophthalmic)/ophthalmics for allergic conjunctivitis
f. Eysuvis (ophthalmic)/ophthalmics, anti-inflammatory/immunomodulator
g. Impeklo lotion (topical)/steroids, topical very high
2. Retrospective drug utilization review (DUR): Conduent, LLC
a. Report on recent retrospective DUR interventions:
b. Report on recent retrospective DUR intervention outcomes:
c. Retrospective DUR proposals: (vote required)
3. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required)
a. Anxiolytic and sedative/hypnotics
b. HAE agents
c. Hyperlipidemia agents
d. Multiple sclerosis agents - new criteria (safety checks)
a. Aerosolized agents - metered-dose inhalers (MDIs): anticholinergic drugs
b. Aerosolized agents - MDIs: anti-inflammatory drugs
c. Aerosolized agents - MDIs: beta2 agonists (long-acting)
d. Aerosolized agents - MDIs: beta2 agonists (short-acting)
e. Antidepressant drugs – other
f. Antidepressant drugs – SSRIs
© 2003-2025 Swagit Productions, LLC